Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study

Authors Lökk J 

Published 31 March 2010 Volume 2010:6(1) Pages 93—97

DOI https://doi.org/10.2147/NDT.S9138

Review by Single anonymous peer review

Peer reviewer comments 3



Johan Lökk

Institution of Neurobiology, Caring Sciences, and Society, Karolinska Institute, Stockholm, Sweden

Background: Patients with Parkinson’s disease (PD) or Parkinsonian syndromes often report excessive daytime sleepiness (EDS). The aim of this study was to evaluate the effects of the psychostimulant modafinil on elderly, institutionalized, severely impaired PD patients with EDS.

Method: A three-week open study on ten institutionalized PD patients scoring >10 points on the Epworth Sleepiness Scale (ESS) with modafinil eventually on 100 mg twice a day. Patients were assessed at the start, week 1, and week 3 with ESS, Clinical Global Impression (CGI) scale severity of PD and appetite.

Results: Reduction of ESS score and PD severity over time were found as well as a significant increase in appetite and reduction in CGI score.

Conclusion: Modafinil 100 mg twice a day was safe and modestly effective for the treatment of EDS in elderly, institutionalized PD patients. Sustaining wakefulness throughout all stages of PD is crucial for participating in life, maintaining social life, and improving quality of life.

Keywords: Parkinson’s disease, daytime sleepiness, Epworth sleepiness scale, psychostimulant

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.